A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Sponsor: Eucure (Beijing) Biopharma Co., Ltd
A PHASE1 clinical study on Advanced Solid Tumor, this trial is completed. The trial is conducted by Eucure (Beijing) Biopharma Co., Ltd and has accumulated 10 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Oct 2023 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Feb 2021 — Jan 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eucure (Beijing) Biopharma Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .